
Summit’s dual-acting drug scores lung cancer win
Summit Therapeutics and Akeso’s closely watched dual-acting lung cancer drug ivonescimab combined with chemotherapy significantly delayed disease progression when compared to the immunotherapy Tevimbra and chemo, according to results of a trial in Chinese …